This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.90% per year. These returns cover a period from January 1, 1988 through December 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Healthcare ETFs in Focus on UnitedHealth's Q4 Earnings
by Sweta Killa
UnitedHealth Group reported mixed fourth-quarter 2019 results wherein it breezed past the Zacks Consensus Estimate on earnings but lagged on revenues.
Bet on Favorite Sector ETFs & Stocks This Earnings Season
by Sweta Killa
Like the first three quarters of 2019, the earnings picture looks weak for Q4 thanks to tough comparisons and moderating economic growth.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Deal or No Deal: Healthcare ETFs to Make a Sweep in 2020
by Sanghamitra Saha
While all eyes are on the fate of the phase one trade deal between the United States and China, Healthcare sector can forget tension and soar higher in 2020 even if there is no deal.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Sweta Killa
Sector ETF report for PSCH
Follow Morgan Stanley to Trade 2020 Election With ETFs
by Sweta Killa
Morgan Stanley outlined four outcomes of the 2020 election and its strategies for investors on how to make the most of them.
Are Investors "Buying Dreams," Not Earnings? ETFs to Play
by Sanghamitra Saha
Some market watchers believe that investors are overlooking earnings weakness and betting big on stocks buoyed by hopes. However, it isn't a weak earnings season for all sectors.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
What's in Store for Healthcare ETFs in Q3 Earnings?
by Sweta Killa
With earnings surprise in the cards, the healthcare sector is expected to witness modest earnings growth of 0.3% in the third quarter, suggesting some room for potential upside for healthcare ETFs.
Healthcare ETFs to Buy on UnitedHealth's Solid Q3 Earnings
by Sweta Killa
Investors could tap the company's strong growth story with ETFs having the largest allocation to this health insurance giant.
JNJ Beats, Ups View: Healthcare ETFs to Buy
by Sweta Killa
Johnson & Johnson continued its long streak of earnings beat and outpaced revenue estimates. It also raised its guidance for the full year.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Sweta Killa
Sector ETF report for PSCH
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Sweta Killa
Sector ETF report for PSCH
Q2 Earnings Surprise in the Cards, Healthcare ETFs to Buy
by Sweta Killa
With earnings surprise in cards, the healthcare sector is expected to witness earnings growth of 1.7% in the second quarter, suggesting continued outperformance for healthcare ETFs.
Healthcare ETFs in Focus on UnitedHealth's Q2 Earnings
by Sweta Killa
ETFs having the largest allocation to this health insurance giant are in focus post Q2 earnings.
Healthcare ETFs in Focus on JNJ's Q2 Earnings Beat
by Sweta Killa
Johnson & Johnson beat the second-quarter earnings and revenue estimates but warned on competition from generics and biosimilars that could impact its third-quarter results.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Sweta Killa
Sector ETF report for PSCH
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Sweta Killa
Sector ETF report for PSCH
Can Q1 Earnings Lift Healthcare ETFs Higher?
by Sweta Killa
With negative earnings revisions, the healthcare sector is expected to witness earnings growth of 1.8% in the first quarter, suggesting smooth trading for healthcare ETFs.
UnitedHealth Falls Despite Q1 Beat, Healthcare ETFs in Focus
by Sweta Killa
UnitedHealth Group reported robust first-quarter 2019 results. The company breezed past the Zacks Consensus Estimate on both earnings and revenues and raised its full-year forecast.
JNJ Beats, Ups Sales Growth View: Healthcare ETFs in Focus
by Sweta Killa
Johnson & Johnson continued its long streak of earnings beat and also outpaced revenue estimates. Though it raised the guidance for full-year sales growth, it tightened the earnings per share forecast.
Healthcare's Near-Term Prospects Bright: 3 ETFs in Focus
by Sweta Jaiswal, FRM
The healthcare space might have seen a sluggish year so far. But its valuation and near-term prospects make it a good space for investments right now.